Contact MENU

News

Showing posts for — Author: kioradev

07.31.19

EyeGate Pharma Announces Randomization of First 25% of Patients in Pivotal Study

WALTHAM, Mass., July 31, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
07.09.19

EyeGate Files FDA Submission to Initiate PE Pilot Study

WALTHAM, Mass., July 9, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
06.26.19

EyeGate Announces First Patient Enrolled in PRK Pivotal Study

WALTHAM, Mass., June 26, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today it has enrolled the first patient in its corneal wound repair pivotal...
Read more
06.03.19

EyeGate Receives Approval from FDA to Initiate PRK Pivotal Study

WALTHAM, Mass., June 3, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today it has received approval from the U.S. Food and Drug Administration (“FDA”)...
Read more
05.14.19

EyeGate Pharma Receives Positive Nasdaq Listing Determination

WALTHAM, Mass., May 14, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request...
Read more
05.08.19

EyeGate Pharma Reports First Quarter 2019 Financial Results and Provides Business Update

WALTHAM, MA, May 8, 2019 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced financial results for the quarter ended March 31, 2019 and provided an update...
Read more
05.02.19

EyeGate Files IDE with FDA for PRK Pivotal Study

WALTHAM, Mass., May 2, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today it has successfully submitted the Investigational Device Exemption (“IDE”) to the U.S....
Read more
03.26.19

EyeGate Confirms Path to De Novo Filing with FDA

WALTHAM, MA / ACCESSWIRE / March 26, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company") has met with the U.S. Food and Drug Administration ("FDA") regarding its Ocular...
Read more

Stay up to date with the latest company news

Sign Up